PharmAust Limited (PAA.AX)

AUD 0.23

(6.98%)

Market Cap (In AUD)

111.92 Million

Revenue (In AUD)

-

Net Income (In AUD)

-9.03 Million

Avg. Volume

934.06 Thousand

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.068-0.535
PE
-
EPS
-
Beta Value
1.552
ISIN
AU000000PAA1
CUSIP
Q9030K284
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Michael Thurn Ph.D.
Employee Count
-
Website
https://www.pharmaust.com
Ipo Date
2001-10-05
Details
PharmAust Limited develops targeted cancer therapeutics for humans and animals in Switzerland, Australia, Sweden, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers, and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of cancer. The company also provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries worldwide. The company has a research agreement with the Walter and Eliza Hall Institute to investigate the effects of MPL upon human T-lymphotrophic virus-1 (HTLV-1) infections in vitro. It serves drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.

More Stocks